Biotech, RNA Interference, Life Sciences
MDRNA Shrinks Board of Directors
Luke Timmerman 5/21/09
MDRNA (NASDAQ: MRNA), the Bothell, WA-based developer of RNA interference drugs, said today it has reduced its board from eight members to five as part of its cash conservation efforts. Former CEO Steven Quay, Alex Cross, and Jack Pollack are off the new board, while Bruce Thaw, Dan Peters, James Rothman, Greg Sessler, and CEO J. Michael French will remain on the board, after yesterday’s annual shareholder meeting.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
